Literature DB >> 34752088

Proteome-Informed Machine Learning Studies of Cocaine Addiction.

Kaifu Gao1, Dong Chen1, Alfred J Robison2, Guo-Wei Wei1,3,4.   

Abstract

No anti-cocaine addiction drugs have been approved by the Food and Drug Administration despite decades of effort. The main challenge is the intricate molecular mechanisms of cocaine addiction, involving synergistic interactions among proteins upstream and downstream of the dopamine transporter. However, it is difficult to study so many proteins with traditional experiments, highlighting the need for innovative strategies in the field. We propose a proteome-informed machine learning (ML) platform for discovering nearly optimal anti-cocaine addiction lead compounds. We analyze proteomic protein-protein interaction networks for cocaine dependence to identify 141 involved drug targets and build 32 ML models for cross-target analysis of more than 60,000 drug candidates or experimental drugs for side effects and repurposing potentials. We further predict their ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties. Our platform reveals that essentially all of the existing drug candidates fail in our cross-target and ADMET screenings but identifies several nearly optimal leads for further optimization.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34752088      PMCID: PMC9357290          DOI: 10.1021/acs.jpclett.1c03133

Source DB:  PubMed          Journal:  J Phys Chem Lett        ISSN: 1948-7185            Impact factor:   6.888


  61 in total

1.  The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access.

Authors:  Laura Orio; Sunmee Wee; Amy H Newman; Luigi Pulvirenti; George F Koob
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

Review 2.  Human ether-à-go-go-related potassium channel: exploring SAR to improve drug design.

Authors:  Maria Maddalena Cavalluzzi; Paola Imbrici; Roberta Gualdani; Angela Stefanachi; Giuseppe Felice Mangiatordi; Giovanni Lentini; Orazio Nicolotti
Journal:  Drug Discov Today       Date:  2019-11-19       Impact factor: 7.851

3.  Dopamine D₃ receptor alterations in cocaine-dependent humans imaged with [¹¹C](+)PHNO.

Authors:  David Matuskey; Jean-Dominique Gallezot; Brian Pittman; Wendol Williams; Jane Wanyiri; Edward Gaiser; Dianne E Lee; Jonas Hannestad; Keunpoong Lim; Minq-Qiang Zheng; Shu-fei Lin; David Labaree; Marc N Potenza; Richard E Carson; Robert T Malison; Yu-Shin Ding
Journal:  Drug Alcohol Depend       Date:  2014-03-20       Impact factor: 4.492

Review 4.  A systematic review of modafinil: Potential clinical uses and mechanisms of action.

Authors:  Jacob S Ballon; David Feifel
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 5.  Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.

Authors:  Maarten E A Reith; Bruce E Blough; Weimin C Hong; Kymry T Jones; Kyle C Schmitt; Michael H Baumann; John S Partilla; Richard B Rothman; Jonathan L Katz
Journal:  Drug Alcohol Depend       Date:  2014-12-18       Impact factor: 4.492

Review 6.  Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.

Authors:  Chloe J Jordan; Jianjing Cao; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-19       Impact factor: 5.250

Review 7.  Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates.

Authors:  Kyle C Schmitt; Richard B Rothman; Maarten E A Reith
Journal:  J Pharmacol Exp Ther       Date:  2013-04-08       Impact factor: 4.030

8.  Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.

Authors:  V Román; I Gyertyán; K Sághy; B Kiss; Zs Szombathelyi
Journal:  Psychopharmacology (Berl)       Date:  2012-11-09       Impact factor: 4.530

9.  New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders.

Authors:  Amy Hauck Newman; Therese Ku; Chloe J Jordan; Alessandro Bonifazi; Zheng-Xiong Xi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2021-01-06       Impact factor: 16.459

10.  Comparability of mixed IC₅₀ data - a statistical analysis.

Authors:  Tuomo Kalliokoski; Christian Kramer; Anna Vulpetti; Peter Gedeck
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.